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1. Introduction 
The danger and the increasing prevalence of heart diseases world wide are now of a great 
concern and are attributed to the cardiovascular risk factors. Cardiovascular risk factors 
have been identified to be the underlying latent or potent causes of death in all heart 
diseases and also in many other disease states such as diabetes. Reduction in the risk factors 
with synthetic drugs or drugs of natural products origin in the course of treatment of some 
disease states where implicated has been found to improve tremendously the health of the 
patient. 
Cardiovascular risk factors include triacylglycerols (triglycerides), cholesterol, cholesteryl 
esters, very low density lipoprotein–cholesterol (VLDL-c), low density lipoprotein-
cholesterol (LDL-c), and anti-athrogenic high density lipoprotein–cholesterol (HDL-c) and 
are collectively referred to as plasma lipids. An increase in plasma lipids concentrations 
beyond certain level give rise to physiological condition known as “Hyperlipidemia”. 
Hyperlipidemia is, therefore, characterized by abnormal elevation in plasma triglyceride, 
cholesterol and low density lipoprotein-cholesterol (LDL-c) and very low lipoprotein -
cholesterol (VLDL-c)  and has also been reported to be the most prevalent indicator for 
susceptibility to atherosclerotic heart disease (Maruthapan and Shree, 2010). Managing 
cardiovascular disease states, therefore, requires drugs that would be capable of lowering 
blood plasma lipids in order to reduce mortality and morbidity associated with the 
cardiovascular complications (Hasimun et al., 2011). It has been reported in epidemiological 
studies that a strong positive correlation exists between  increase in the blood cholesterol 
level and incidence of cardiovascular heart disease (CHD) (Hamed et al., 2010; Imafidon 
2010;  Maruthapana and Shree 2010), and also increase in the incidence of 
atherosclerosis(Hasimun et al., 2011). A strong relationship between increase in C-reactive 
protein (CRP) and cardiovascular risk factors has also been reported as well as increase in 
myocardial infection and coronary artery disease among individuals with angina pectoris 
(Ghayour –Mobarhan et al. 2007). 
Atherosclerosis arises from the deposition of fatty substances, cellular waste products, 
calcium and fibrin in the arteries, resulting in clotting (Lewis et al., 2002) and is considered 
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one of the major causes of coronary heart disease. It is recognized as a common threat to life, 
usually seen in individuals consuming high quantities of cholesterol and saturated fats in 
their diets. It has also been established in animal studies that raising dietary cholesterol 
alone could increase atherosclerosis susceptibility (Madhumathi et al., 2006). Atherosclerosis 
is characterized by endothelia dysfunction, muscular inflammation resulting from build up 
of plasma lipids which tantamount to vascular remodeling, acute and chronic luminal 
obstruction, abnormalities in the blood flow and diminished oxygen supplies to target 
organs (Madhumathi et al., 2006). The development of atherosclerosis could also be 
attributed to other factors such as oxidative stress which is responsible for the oxidation of 
low-density lipoprotein-cholesterol (LDL-c) and is considered as one of the first steps of 
atherosclerotic pathogenesis. Local inflammatory processes have also been identified to play 
a crucial role in the transition from reversible accumulation of cholesterol in the arterial wall 
to irreversible damage of the arteries (Brunner-La Rocca1, et al., 2005). Many factors 
contributing to etiology of atherosclerosis in addition to diet include diabetes mellitus, 
psychological factors and the presence of glucocorticoids.   
Diabetes mellitus (DM) is a major degenerative disease in the world today afflicting many 
lives both in the developed and developing countries (Ogbonnia et al., 2011). It has been 
succinctly described as the common metabolic disorder of carbohydrate and fat metabolism, 
which is due to absolute or relative lack of insulin and is characterized by hyperglycaemia 
and hyperlipidemia (Sharon and Marvin, 1975; Walter, 1977). Diabetes is a multiple disease 
state and has been defined as “a state of premature cardiovascular death that is associated 
with chronic hyperglycemia and also associated with blindness and renal failure” (Fisher 
and Shaw, 2001). This assertion was to draw attention and to encourage multiple clinical 
approaches that would altogether help reduce cardiovascular risk factors in diabetic patients 
(Ogbonnia et al., 2011). Diabetes especially the type 2 model might be postulated to occur 
primarily due to underlying abnormality of insulin resistance - that is resistance of the body 
to the biological actions of insulin. The consequences of insulin resistance lead to 
hyperinsulinaemia and are associated with CRFs - dyslipidaemia including athrogenic lipid 
profile with increase in low and very-low density lipoprotein-cholesterols (LDL-c and 
VLDL-c) and reduction in the anti-athrogenic high density lipoprotein-cholesterol (HDL-c). 
Cardiovascular risk factors have been implicated and even occur at a frequency much 
higher than expected in some other disease states such as benign prostatic hyperplasia 
(BPH). Benign prostatic hyperplasia is a neoplastic enlargement of the prostate gland and is 
common in elderly men (Ejike and Ezeanyika, 2010). Epidemiological studies have 
demonstrated that many of the risk factors associated with cardiovascular diseases are the 
same as found in BPH (Dharmananda, 2011), and these risk factors include obesity, 
hypertension and diabetes. The diabetes connection may be considered very strong and the 
risk centers on the non-insulin dependent diabetes mellitus (NIDDM) which most often 
involves excessive insulin levels, a possible direct contributor to the growth of the prostrate 
(Hammarten and Hogstedt, 2011). The treatment of BPH became a medical issue mainly in 
1970s at the same time that the cardiovascular disease therapy came to fore and the 
incidence of the disease has become higher (Dharmananda, 2011). Herbal or phytomedicines 
are now being investigated with some recorded successes for the management of 
cardiovascular risk factors with the accompanied disease states. Herbal remedies with active 
components understood to be sterols, such as beta-sitosterol has been used as a therapeutic 
agent for BPH (Bombardelli and Morazzoni, 1997). 
www.intechopen.com
 
Cardiovascular Risk Factors: Implications in Diabetes, Other Disease States and Herbal Drugs 
 
367 
2. Cardiovascular risk factors  
Cardiovascular risk factors consisting mostly of plasma lipids including triacylglycerol 
(triglycerides), cholesteryl esters and cholesterol are synthesized by the liver and adipose 
tissues and may also be absorbed from the diet (Stryer, 1988). They are also efficiently 
synthesized from carbohydrate diets largely in the intestinal epithelia tissues in addition to 
the liver (Metzler, 1974), and are transported between various tissues and organs for 
utilization and storage. These plasma lipids like other lipids are generally insoluble in water 
and pose a transportation problem in aqueous blood plasma. This problem is overcome by 
associating the nonpolar lipids comprising triacylglycerol (triglycerides) and cholesteryl 
esters with amphipatic lipids such as phospholipids, cholesterol and proteins to produce 
water-miscible lipoproteins (Conn and Stumpf, 1976; Stryer, 1988). A lipoprotein is a particle 
consisting of core hydrophobic lipids surrounded by a shell of polar lipid and apoprotein 
and mediates the cycle by transporting lipids from the intestine as chylomicrons – and from 
the liver as very low density lipoproteins-cholesterol (VLDL-c) - to most tissues for 
oxidation and to adipose tissue for storage. Lipoproteins are grouped according to 
increasing densities by centrifugation as follow:  
i. Chylomicrons which incorporate intestinal absorbed triacylglycerol from intestinal 
absorption of triacylglycerol and other lipids. 
ii. Very low density lipoprotein-cholesterol (VLDL-c, or pre – ┚- Lipoprotein), are derived 
from the combination of newly synthesized triacylglycerol together with small amounts 
of phospholipids and cholesterol and apolipoproteins all synthesized in the liver 
(Stryer, 1988). 
iii. Intermediate density lipoprotein (IDL) 
iv. Low density lipoprotein-cholesterol (LDL-c) (LDL-c or ┚-Lipoproteins), representing a 
final stage in the catabolism of VLDL-c, and 
High density lipoproteins-cholesterol (HDL-c, or ┙-Lipoproteins), involved in cholesterol 
transport and also in VLDL-c and chylomicron metabolism. 
Major groups of lipoproteins have been identified to be physiologically important and are 
used in clinical diagnosis. The primary role of LDL-c appears to be the transport of esterified 
cholesterol to tissue while that of the high density lipoproteins-cholesterol (HDL-c) is to 
carry excess cholesterol away from most tissues to the liver. The size of the lipoprotein 
particles also varies from a 200 – to 500 –nm diameter for chylomicrons to as little as 5 nm 
for the smallest HDL particles (Metzler, 1974). 
Lipoprotein is made up of triacylglycerol (16%) which is the predominant lipid in 
chylomicrons and VLDL-c, while phosholipids (30%) and cholesterol (14%) are the 
predominant lipids of HDL-c and LDL-c respectively and cholesterol esters (36%) (Stryer,  
1988). It also contains much smaller fraction of unesterified long chain fatty acids (free fatty 
acids) which are metabolically the most active of plasma lipids. These constitute what is 
collectively known as ‘Cardiovascular Risk Factors’ which are implicated in many disease 
states as potent or latent causes of death. Lipoproteins may be separated according to their 
electrophoretic properties into: ┙-, ┚-, and pre -┚- Lipoproteins (Holme and Peck, 1998). 
The protein moiety of a lipoprotein is known as apolipoprotein or apoprotein constituting 
nearly 70% of  HDL-c and as little as 1% of chylomicrons. Some apolipoproteins are integral 
and can not be removed, whereas others are free to transfer to other lipoprotiens. Seven 
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principal apoprotein, A – 1, A – 2, A – 4, B – 48, B – 100, C and E have been isolated and 
characterized. They are synthesized and secreted by the liver and the intestine and generally 
have two principal roles: they solubilize highly hydrophobic lipid and also they contain 
signals that regulate the movement of particular lipid into and out of specific target cells and 
tissues.  
Lipoprotein Source/major 
core lipid
Diameter 
(nm)
Density 
(g/mL)
Composition Main Lipid 
Components
Mechanism of 
lipid delivery 
  Protein (%) Lipid 
(%)
< 0.95  
Chylomicrons Dietary 
triacylglycerol 
Intestine
90-1000 < 0.95 1-2 98-99 < 1.006 Hydrolysis by 
lipoprotein 
lipase 
Chylomicrons 
remnants 
Dietary 
cholesterol 
esters 
Chylomicrons
45-150 < 1.006 6-8 92-94 0.95-
1.006 
Receptor-
mediated 
endocytosis 
by liver 
VLDL Endogenous 
triacylglycerols 
Liver 
(Intestine)
30-90 0.95-
1.006 
7-10 90-93 1.006-
1.019 
Hydrolysis by 
liproprotein 
lipase 
IDL Endogenous 
cholesterol 
esters VLDL 
25-35 1.006-
1.019 
11 89 1.019-
1.063 
Receptor-
mediated 
endocytosis 
by liver and 
conversion to 
LDL  
LDL Endogenous 
cholesterol 
esters VLDL 
20-25 1.019-
1.063 
21 79 Receptor-
mediated 
endocytosis 
by liver and 
other tissues 
 Endogenous 
cholesterol 
esters 
Transfer of 
cholesterol 
esters to IDL 
and LDL 
Table 1. Composition of the Lipoproteins in plasma of humans. 
Each apolipoproteins carry out one or more distinct roles. 
i. The apo B, stabilizes lipoproteins micelles and as the sole protein of LDL-c serves the 
function of solubilizing cholesterol within LDL-c complex which in turn increases the 
transport capacity of LDL-c for subsequent deposit on arterial wall (Madhumathi et al., 
2006).  
ii. They are enzyme cofactors. The apoC-II has specific function of activating the 
lipoprotein lipase that hydrolyses triacylglycerols of chylomicrons and VLDL. Lack of 
either C-II or the lipase results in a very high level of triacylglycerol in the blood. 
iii. They act as ligands for interaction with lipoprotein receptors in tissues, e.g apoB-100 
and apo E for the LDL receptors, apo E for the LDL receptor– related protein (LRP) 
which  has been identified as the remnant receptor, and apo A-1 for the HDL-c receptor. 
The function of Apo A-IV and apo D, however, are not yet clearly defined, although 
apo D, is believed to be an important factor in human neurodegenerative disorders. 
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2.1 Cholesterol 
Cholesterol is physiologically very essential for all animal life, and is primarily synthesized 
from simpler substances within the body. It is an amphipathic waxy steroid of fat that is 
manufactured in the liver or intestines. It constitutes essentially structural component of 
membrane required in establishing proper membrane permeability and fluidity and is also a 
constituent of  the outer layer of plasma lipoproteins. Cholesterol is the principal sterol 
synthesized by animals and transported in the blood plasma of all mammals (Leah, 2009). It 
is also an important component implicated in the manufacture of bile acids, steroid 
hormones, and vitamin D  (Jain, 2005; Maxifield and Tabas, 2005; Hasimun, 2011). The 
hydroxyl group on cholesterol interacts with the polar head groups of the membrane 
phospholipids and sphingolipids, while the bulky steroid and the hydrocarbon chain are 
embedded in the membrane, alongside the nonpolar fatty acid chain of the other lipids. In 
this structural form, cholesterol reduces the permeability of the plasma membrane to 
protons (positive hydrogen ions) and sodium ions.  
  
Fig. 1. Chemical structure of cholesterol  
Most cholesterol is carried in the blood by low density lipoprotein (LDL), which delivers it 
directly to cells where it is needed. Both a 74-kDa cholesteryl ester transfer protein and a 
phospholipid transfer protein are also involved in this process. Cholesterol esterases, which 
release free cholesterol, may act both on lipoproteins and on pancreatic secretions. The LDL-
cholesterol complex binds to LDL receptors on the cell surfaces. These receptors are specific 
for apolipoprotein B-100 present in the LDL. The occupied LDL-receptor complexes are 
taken up by endocytosis through coated pits; the apolipoproteins are degraded in 
lysosomes, while the cholesteryl esters are released and cleaved by a specific lysosomal acid 
lipase to form free cholesterol. 
Animal fats are complex mixtures of triglycerides, with fewer amounts of phospholipids 
and cholesterol. As a consequence all food containing animal fats contain cholesterol to 
varying extent. Plasma cholesterol concentration elevation is, therefore ,one of the important 
CRFs as its transportation within lipoprotein is affected and is strongly associated with 
progression of atherosclerosis.    
2.2 Triacylglycerols 
Triacylglycerols (figure 2b see the figure below) serve as biochemical energy reserves in the 
cell and may be oxidized in the liver to provide energy or deposited as depot fat in 
characteristic regions of the animal where they act as a long-term food store and insulator 
(Plummer, 1998). They are the neutral and saponifiable lipids found in most organisms. 
Triacylglycerols (triglycerides) which are chemically fatty acid esters of the trihydroxy 
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alcohol, glycerol (Figure 2a), are compounds that usually make up the bulk of ingested 
lipids and are transported to the blood via the lymphatic system in the form of 
chylomicrons. Triacylglycerols synthesized endogenously as against those obtained from 
the diet, are carried by VLDL produced primarily by the liver (Styer, 1988). Studies have 
suggested that triacylglycerol (TG)-rich lipoprotein(TRL) plays an important role in the 
development of atherosclerosis because both coronary artery  disease and myocardial  
infarction have been associated with abnormal postprandial lipoprotein pattern (Moreno-
Luna et al., 2007) 
                                    
                                    (a)                                                                                      (b) 
Fig. 2. (a) Chemical structure of cholesterol (b) chemical structure of triacylglycerol 
Most of the fatty acids synthesized or ingested by an organism are either transformed into 
triacylgylcerols and stored for metabolism to give energy or incorporated into 
phospholipids components of the membrane. Triacylgylcerols have as precursor fatty acyl-
CoAs and glycerol-β-phosphate but many enzymatic steps are involved in their biosynthesis 
in animal tissues. Although the triglycerides have been found to be important predictors of 
CVD in many studies, no clinical trial data has established that lowering triglycerides in 
individuals with or without diabetes independently leads to lowering of CVD occurring 
rates even after changes in HDL-cholesterol are adjusted for. From the foregoing, it is 
evident that elevated cholesterol, low HDL-c, high TG and high LDL-c are all risk factors for 
CVD. The pattern of occurrence of these abnormalities in type 2 DM especially has been 
severally reported in both developed and developing economies (Idogun et al., 2007; 
Williams et al., 2008). 
2.3 Very Low Density Lipoprotein-cholesterol (VLDL-c or preβ- lipoproteins) 
VLDL-c is synthesized in the liver and contains primarily triglycerides in their lipid cores 
for their export and also some cholesterol ester (Botham and Mayes, 2006). As their 
triglycerides are cleaved by endothelial lipoprotein lipase and transferred to hepatic tissues, 
the VLDL (very-low-density lipoprotein) particles lose most of their apolipoprotein C and 
become intermediate-density lipoproteins. VLDL is one of the five major groups of 
lipoproteins which functions to enable fats and cholesterol to move within the water-based 
solution of the bloodstream. VLDL-c particles have a diameter of 30-80 nm each and 
transports endogenous products such as triglycerides, phospholipids, cholesterol, and 
cholesteryl esters, whereas chylomicrons transport exogenous (dietary) products. It 
functions as the body's internal transport mechanism for lipids. 
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2.4 Low Density Lipoprotein-cholesterol (LDL-c) 
The primary role of LDL-c appears to be the transport of esterified cholesterol to tissues 
(Guyton and Hall, 2006). Low density lipoprotein results when triacylglycerols are released 
from VLDL-c by the action of the same lipase that acts on chylomicrons and the remnants 
which are rich in cholesterol esters are called intermediate density lipoprotein (IDL). IDL 
particles have two fates as half of them are taken up by the liver and the other half 
converted into LDL which is the major carrier of cholesterol in blood (Styer, 1988). LDL-c or 
β- lipoprotein represent the final stage in the metabolism of VLDL. Originally, LDL-
cholesterol was determined by a lengthy, laborious process called ultracentrifugation of 
serum. A much more rapid test became available based on the following Friedwald 
equation: Total cholesterol = LDL-cholesterol + HDL-cholesterol + VLDL-cholesterol 
(VLDL-cholesterol = triglycerides/5). One can rapidly and easily do a lipid profile by 
enzymatically measuring the important lipids—total cholesterol, HDL- cholesterol, and 
triglycerides. Dividing triglycerides by five gives the relatively unimportant, but hard to 
measure, VLDL-cholesterol, which is useful in then calculating the very important LDL 
cholesterol (Holme and Peck, 1998). 
2.5 High Density Lipoprotein-cholesterol (HDL-c or -lipoprotein) 
HDL-c is involved in the cholesterol transport and in VLDL and chylomicron metabolism. 
Unlike LDL which primary role appears to be the carriage of esterified cholesterol to the 
tissues, HDL functions to carry excess cholesterol away from most tissues to the liver. The 
apoA-I present in the HDL-c particle binds lipid and also activates lecithin cholesterol 
acyltransferase (LCAT), which catalyzes formation of cholesteryl esters which migrate into 
the interior of the HDL-c and are carried to the liver (Metzler, 1974). Recent studies on 
patients with LCAT deficiency have shown a modest but significant increase in incidence of 
cardiovascular disease consistent with a beneficial effect of LCAT on atherosclerosis 
(Rousset et al., 2009) HDL particles compared to other lipoproteins, are assembled outside of 
cells from lipids and proteins, some of which may be  donated from chylomicrons or other 
lipoprotein particles. HDL has higher protein content than other lipoproteins and is more 
heterogeneous. The major HDL protein is apolipoprotein A-I, but many HDL particles also 
contain A-II, and apolipoproteins A-IV, D, and E may also be present. A low plasma level of 
HDL-cholesterol is associated with a high risk of atherosclerosis. 
3. Implicated disease states 
3.1 Diabetes 
Diabetes mellitus is a major global health problem and is now recognized as one of the leading 
causes of death in the developing countries, where the high prevalence of the disease could be 
attributed to improved nutritional status coupled with a gross lack of modern facilities for the 
early diagnosis of the disease (Uebanso et al., 2007; Ogbonnia et al., 2008a).  Diabetes mellitus 
(DM) is a complex disease characterized by abnormal pattern of fuel usage resulting from over 
production of glucose and its under utilization by other organs (Stryer, 1988). Diabetes has 
been succinctly described as the common metabolic disorder of carbohydrate and fat 
metabolism, which is due to absolute or relative lack of insulin and is characterized by 
hyperglycaemia (Walter, 1977; Shah et al., 2008 and Sharma et al., 2010; Dinesh et al., 2011). 
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Diabetes mellitus is therefore a multifactorial disease associated with hyperglycemia, (Shah et 
al., 2008; Sharma et al., 2010); lipoprotein abnormalities, raised basal metabolic rate and high 
oxidative stress inducing damage to beta cells. The abnormalities in carbohydrates and lipid 
metabolism in diabetes also result in excessive production of reactive oxygen species (ROS) 
and defect in ROS scavenging enzymes in addition to oxidative stress. The low level of insulin 
associated with diabetes has been found to increase the activity of anti-enzyme, fatty acyl 
Coenzyme A oxidase, which initiates the  β-oxidation of the fatty acids, resulting in lipid 
peroxidation (Shah et al., 2008). Increased lipid peroxidation has also been found to impair 
membrane function by decreasing membrane fluidity and changing the activity of the 
membrane-bound enzyme and receptors. The resulting lipid radicals and lipid peroxides are 
harmful to the cell in the body and are associated with atherosclerosis and brain damage.  
Chronic hyperglycemia which occurs in diabetes causes glycation of body proteins which in 
turn leads to secondary complications affecting eyes, kidneys, nerves and arteries (Mishra 
and Garg, 2011). These may be delayed, lessened or prevented by maintaining blood glucose 
values close to normal in modern medicine, though no satisfactory effective therapy is  
available for total cure of diabetes mellitus. 
Diabetes mellitus is also associated with hyperlipidaemia with profound alteration in the 
concentrations and compositions of plasma lipid. Changes in the concentration of the lipids 
in diabetes contribute to the development of vascular disease. Excessive levels of blood 
cholesterol accelerate atherogenesis and lowering high blood cholesterol reduces the 
incidence of CHD (Grundy, 1986). One of the risk factors for coronary heart disease is 
elevated total cholesterol (TC), low density lipoprotein-cholesterol (LDL-c) and lowered 
high density lipoprotein-cholesterol (HDL-c). The development of cardiovascular disease in 
DM is often predicted by several factors which include central obesity, hypertriglyceridemia 
and hypertension. Hypertriacylglyceridemia and low high-density liopoproteinaemia are 
two components of the atherogenic profile seen in DM. Elevated low density lipoprotein-
cholesterol (LDL-c) has also been found to be an independent risk factor for the 
development of cardiovascular disease and is often reported to be the commonest lipid 
abnormality found in patients with DM (Udawat  and Goyal, 2001; Idogun et al., 2007). 
3.2 Atherosclerosis  
Atherosclerosis or arteriosclerosis is a disease of large and medium size muscular arteries 
and is characterized by endothelial dysfunction vascular inflammation and build up of 
lipids, cholesterol, calcium and cellular debris within intima of vessel wall. This build up 
results in plaque formation, vascular remodeling, acute and chronic luminal obstruction, 
abnormalities in the blood flow and diminished oxygen supply to the target organ. 
(Madhumathi et al., 2006). Atherosclerotic disease has been found to be the most common 
cause of myocardial ischemia. Myocardium is said to be ischaemic when the pumping 
capability of the heart is impaired as a result of fall in the coronary blood flow which could 
not meet up with the metabolic need of the heart. In artherosclerotic disease, there is a 
localised lipid deposits  called plaques develop within the arterial walls. In the severe cases 
of the disease these plaques become  calcified and are so large that they physically narrow 
the lumen of the arteries producing stenosis (Mohrman and Heller, 2006). umerous studies 
have revealed important risk factors for the development of arthrosclerosis and these 
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include diseases such as diabetes mellitus, arterial hypertension, and also smoking and 
elevated blood cholesterol  
Current concepts in atherosclerosis suggest that oxidation of LDL-c is involved in its 
pathogenesis. The critical role of oxidized LDL-c in atherogenesis may be due to its rapid 
uptake by the foam cells lining the arterial intima, which are thought to have macrophage-
like properties. When LDL-c is oxidized chemotactic effect is exerted on monocytes and this 
increase the uptake of LDL-c leading to the formation of arterial plaque. Lipid oxidation can 
be inhibited by the use of antioxidants such as vit E which inhibit the formation of lesions in 
hypercholesterolemic rabbits (Chein  and Frishman, 2003). 
Hypercholesterolemia has also been implicated in the process of atherogenesis and a 
curvilinear relationship has been documented between increasing cholesterol and increasing 
incidence of CVD (Brunzell et al., 2008). The role of LDL-c in the development of CVD 
cannot be overemphasized as there is documented evidence that high levels of LDL-c not 
only cause atherosclerosis but pharmacological interventions that reduce LDL-c are 
associated with stabilization and regression of atherosclerosis in proportion to the 
cholesterol lowering achieved (O'Keefe et al., 2004). Low levels of HDL-c have been 
consistently reported in cardiovascular diseases (Idogun  et al., 2007; Sani-Bello et al., 2007, 
Singh et al., 2007). Primary treatment of coronary artery disease (and atherosclerosis in 
general) should include attempts to lower blood lipid by dietary and pharmacological 
techniques to prevent and possibly reverse further deposit of plaques.  
3.3 Benign Prostatic Hyperplasia (BPH) 
Benign Prostatic Hyperplasia (BPH) is a neoplastic enlargement of the prostate gland, and is 
a common problem among aging men (Ejike and Ezeanyika, 2010; Dharmananda, 2011). The 
etiology of this disease is still poorly understood, but it has been proposed to have two 
phases: 
One of the phases involves no clinical sign but there maybe some microscopic changes while 
the other manifests as the disorder of urination caused by the obstruction of the urinary tract 
by an enlarged prostate gland (Dharmananda, 2011). 
Epidemiological studies have demonstrated that many of the risk factors associated with 
cardiovascular diseases apply also as risk factors for BPH. The problems associated with 
diabetic  may be considered very strong as the risk in non-insulin dependent diabetes 
(NIDDM); which most often connected with insulin resistance may be a possible direct 
contributor to the growth of BPH (Dharmananda, 2011). NIDDM which arises from either 
impairment of insulin utilization or dysfunction on the metabolism of carbohydrates, fats 
and protein or both culminates in hyperlipidemia- hence elevation in plasma cardiovascular 
risk factor. BPH is therefore associated with metabolic syndrome (Kasturi et al., 2006; 
Ozden, 2007). 
4. Herbal drugs used to control CRF in the disease states 
Herbal medicines may be described as medicines prepared either with a single plant part or 
combinations of different plant parts either fresh,dried or as extract are now recognized as 
www.intechopen.com
 
The Cardiovascular System – Physiology, Diagnostics and Clinical Implications 
 
374 
potent therapeutic agents. Plants derived medicines commonly referred to as 
“phytomedicines” have been effectively employed in the management of variety of 
pathological conditions and are associated with fewer side effects (Nirmala et al., 2011; 
Ogbonnia et al, 2011). In recent years, they have been found to be effective both as 
hypoglycaemic and hypolipidemic agents (Ogbonnia et al., 2008c; 2010b) and have also been 
empirically used by many people from various cultures to lower cholesterol levels (Hamed, 
et al., 2010). Herbal medicines owe their therapeutic activities to the presence in them of 
secondary organic compounds or natural products constituents called the ‘active 
constituents’. 
4.1 Herbal active constituents 
Herbal drugs contain natural products or secondary metabolites as the active constituents 
responsible for their physiological and pharmacological activities. The physiological and 
pharmacological activities have been found amongst alkaloids, phenolics and flavonoid 
compounds, glycosides (steroidal and saponins), and terpenoids, and is brought about 
through one or combination of two or more of the mechanisms  that are the same as in the 
disease state they are being used. The mechanisms of their antidiabetic and antilipidemic 
activities which contribute to lowering of plasma lipids are the same mechanisms 
responsible for lowering of cardiovascular risk factors. These include the following: 
Glycosidase (Glucosidase) inhibition mechanism; alpha-amylase inhibition mechanism; 
antioxidant activities mechanism; inhibition of hepatic glucose metabolizing enzymes 
mechanism and inhibition of glycosylation of haemoglobin mechanism. These different 
mechanisms of activities are briefly discussed below 
4.2 Possible mechanism of actions 
The different classes of secondary product active constituents present in different herbal 
medicines may act through one or different mechanisms to bring about lowering or clearing 
of cardiovascular risk factors in a patient which may be probably the same mechanism 
through which they act exert their pharmacological action to control the disease state in 
question.   Notably some of these possible mechanisms of actions may include: 
4.2.1 Glycosidase (Glucosidase) inhibitor mechanism 
One of the earliest features of type II diabetes and also observed in pre-diabetic phase is the 
loss of early phase secretion of insulin. Early phase insulin secretion is seen after a meal or 
after oral or intravenous ingestion of glucose and it is responsible for inhibition of hepatic 
glucose output and its absence results in postprandial hyperglycemia. (Ogbonnia and 
Anyakora 2009c). The ┙-glucosidase inhibitors category of drugs have been found to 
decrease postprandial glucose level by interfering with carbohydrate digestion and delaying 
gastrointestinal absorption of glucose . Slowing down digestion and breakdown of starches 
may have beneficial effects on insulin resistance and glycaemic index control on people 
suffering from diabetes. In this group some cryptic or water soluble alkaloids especially 
polyhydroxy alkaloids, have been identified to be potent glucosidase inhibitor (Kameswara 
et al., 2001). This as a whole comprises of relatively simple monocyclic pyrrolidine and 
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piperidine alkaloids, necines, amino alcohols which are derivatives bicyclic pyrrolizidine, 
and are mostly esters of amino alcohols and of aliphatic carboxylic acids. 
4.2.2 Inhibition of hepatic glucose metabolizing enzymes mechanism 
Synthesis of glucose by the liver and kidney from non carbohydrate precursor such as 
lactate, glycerol and amino acid constitutes a process known as gluconeogenesis. The liver 
hydrolytic enzymes glucose-6-phosphatase and fructose-1, 6- diphoshatase have been 
shown to play a crucial role in gluconeogenesis contributing to hyperglycaemic condition 
found in diabetes. Herbal drug products may act by binding with the enzymes. Treatment 
with an herbal drug has been observed to decrease the activities of these liver enzymes 
significantly with a concomitant decrease in blood sugar level (Lazar, 2006). 
4.2.3 Antioxidants effects 
Phenolics and polyphenolics are associated with antioxidant properties and  have been 
reported to categorically reduce the oxidation of the LDL-c (Kar, 2007). Flavonoids in 
hawthorn extract have been found to reduce wall tension in normal and sclerotic blood 
vessels. These chemicals are also presumed to stimulate beta-2-receptors and thus widen 
coronary arteries and blood vessels in skeletal muscle . Flavonoids and other antioxidants 
act to destroy free radicals which are particles that can damage cell membranes, interact 
with genetic material and possibly develop heart diseases and cancer. They have also been 
found to decrease two other markers of cardiovascular disease, homocysteine and C-
reactive protein. C-reactive protein (CRP) has been reported to be associated with increased 
risk of cardiovascular disease, myocardial infection (MI) coronary artery disease mortality 
among individuals with angina pectoris. 
Oxidative stress has been reported to increase in diabetic patients and is regarded as 
common pathway by which many classical cardiovascular disease (CVD) risk factors and 
postprandial dysmetabolism may initiate and promote atherosclerosis (WHO 1985). Studies 
have shown that treatment with antioxidant reduces diabetic complications (Negappa et al., 
2003). Flavonoids have been shown to scavenge reactive oxygen species (ROS) that are 
produced under severe stress conditions and protect plant cell and animal cell from 
oxidative stress and may have important role in human health.  
4.2.4 Inhibition of glycosylation of haemoglobin mechanism 
It has now become apparent that both fasting and postprandial hyperglycaemia contributes to 
overall glycaemic burden and therefore total glycosylation of haemoglobin, HbA., Many 
studies have shown that there is substantial evidence and a very strong correlation between 
hyperglycaemia and the risk of developing cardiovascular disease and mortality. Postprandial 
hyperglycemia has been found to occur together with postprandial hyperlipidaemia which is 
also associated with increased oxidative stress and endothelia dysfunction. However, one 
could therefore postulate that herbal drug products that are effective in the reduction of 
postprandial hyperglycaemia may not only play a role in managing type II diabetes but could 
also offer a tantalizing possibility of reducing cardiovascular risk.  
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S/no Plant/Herbal Drugs Work Done Reference 
1. Alstonia congensis 
Engler (Apocynaceae) 
bark and Xylopia 
aethiopica (Dunal) A. 
Rich (Annonaceae) fruits
Evaluation of acute in mice 
and subchronic toxicity 
Ogbonnia et al., 2008a 
2 Leone Bitters, a Nigerian 
polyherbal formulation 
Antimicrobial evaluation, 
acute and subchronic toxicity 
studies 
Ogbonnia et al., 2008a, 
2010a 
3. Parinari curatellifolia 
Planch, 
(Chrysobalanaceae) 
seeds 
Assessing plasma glucose 
and lipid levels, body weight 
and acute toxicity following 
oral administration of an 
aqueous ethanolic extract. 
Ogbonnia et al., 2008b 
4. poly-herbal formulation on alloxan- induced diabetic 
rats 
Ogbonnia et al., 2008b, 
2010b 
5. Treculia africana Decne 
and Bryophyllum 
pinnatum Lam 
Evaluation of Hypoglycaemic 
and Hypolipidaemic Effects 
of Aqueous Ethanolic 
Extracts 
Ogbonnia et al., 2008c 
6. Stachytarpheta 
angustifolia 
Evaluation of acute and 
subchronic toxicity in animals 
and phytochemical profile 
Ogbonnia et al., 2009a 
7. Parinari curatellifolia 
Planch 
(Chrysobalanaceae) 
seeds 
Evaluation of acute in mice 
and subchronic toxicity 
Ogbonnia et al., 2009b 
8. Parinari  curatellifolia 
and Anthoclista vogelli
Diabetes and cardiovascular 
factors
Ogbonnia et al., 2011 
9. Azadirachta indica Diabetes Mellitus and 
hypolipidemic effects 
Dinesh et al., 2011    
10. Holarrhena 
antidysenterica
Diabetes Ali et al., 2009 
11. 
 
Annona muricata Linn
Centratherum 
anthelmintica
Diabetes 
Diabetes 
Shah et al., 2008 
12. Grape seed extract cholesterol http://www.nativeremed
ies.com/article/cholestero
l-education-heart-
disease.html 
13. 
 
Red yeast rice  contains a 
natural form of 
lovastatin
cholesterol
14. Vilis vinifera extract and 
Oroxylum indicum
cholesterol D’Mello et al., 2011 
15. Garlic Cholesterol, antithrombic
Cardiovascular diseases  
 
Hoareau and DaSilva,1999 
16. Hawthorn leaf and 
flower 
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17. Cinnamomic camphoric 
aetherolleum 
Coronary artery disease 
(CAD)  
 
 
 
 
 
 
 
18. Rosmarini folium 
(Rosemary leaf) 
19. Pini aetheroleum(pine 
neddle) 
20. Eucalypti folium 
(Eucalyptus leaf) 
21. Menthae aetheroleum 
(menthol) 
22. Bacopa monnieri  Linn Diabetes Ghosh et al., 2006 
23. Feronia elephantum Corr Diabetes  Mishra and Garg, 2011 
24. Achilleamellifolium 
(yarrow) Convallaria 
majalis (lilly of the 
valley)Crategeus 
laevigata (hawthorn) 
Cynarascolymus 
(globeantichoke) 
Gingko biloba  (gingko) 
Vibumum opulus  
Cardiovascular diseases Hoareau and DaSilva, 
1999 
Table 2. Some researched plants and plant medicines found to have lowering effects on 
cardiovascular risk factors. 
5. Summary 
• The danger and the increasing prevalence of heart diseases world over are now of a 
great concern 
• These diseases could be attributed to the cardiovascular risk factors which also have 
been identified to be the underlying latent or potent causes of death in heart diseases in 
particular and also in many other disease states 
• Cardiovascular risk factors include triacylglycerols (triglycerides), cholesterol, 
cholesteryl esters, very low density lipoprotein – cholesterol (VLDL-c), low density 
lipoprotein-cholesterol (LDL-c), and anti-athrogenic HDL which are collectively 
referred to as plasma lipids 
• Cholesterol is a fat-like substance that is present in cell membranes and is a precursor to 
steroid hormones and bile acids. 
• Coronary atherosclerosis is the deposition of cholesterol and fibrin complexes within 
the lumen of a coronary artery that narrows the lumen, thereby limiting blood flow. 
• Coronary heart disease (CHD) is atherosclerosis of one or more coronary arteries that 
has resulted in symptomatic disease such as angina pectoris, myocardial infarction, or 
congestive heart failure, or has required coronary artery surgery or coronary 
angioplasty. 
• Lipoproteins are lipid-containing proteins in the blood that transport cholesterol 
throughout the body. 
• Disease states with underlying cardiovascular risk factors include diabetes, 
atherosclerosis and benign prostatic hyperplasia.  
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